STF-31 是一种葡萄糖转运蛋白 1 (GLUT1) 的选择性抑制剂,IC50值为 1 μM。STF-31 也是一种NAMPT抑制剂。STF-31 抑制肾细胞癌 (RCC) 4 细胞中的葡萄糖摄取。
生物活性 | STF-31 is a selective inhibitor ofglucose transporter 1 (GLUT1), with anIC50of 1 μM. STF-31 is also aNAMPTinhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells[1][2]. |
IC50& Target[2] | |
体外研究 (In Vitro) | STF-31 (0.01-10 μM; 10 days) is specifically toxic to RCC4 cells, whereas RCC4/VHL cells are relatively unaffected. RCC4/VHL cells treated with STF-31 (5 μM; 10 days) largely recovery, whereas RCC4 cells under the same conditions does not[1]. STF-31 (1.25-5 μM; 3 days) does not induce autophagy, apoptosis, or DNA damage. STF-31 causes a necrotic cell death[1]. STF-31 reduces the efferocytosis of wild type and SLC2A1-overexpressing LR73 cells[4].
Cell Viability Assay[1] Cell Line: | Wild-type RCC4 cells (RCC4/VHL) and RCC4 cells without VHL | Concentration: | 0.01, 0.1, 1, 10 μM | Incubation Time: | 10 days | Result: | Reduced viability of RCC4 cells without VHL in a concentration-dependent manner when compared to their wild-type counterparts. |
|
体内研究 (In Vivo) | STF-31 (10 mg/kg; i.p.; twice daily for 2 days, followed by once daily for another 3 days) does not affect normal mice body weight, behavior, and ERG responses. STF-31 reduces light-inducedCX3CR1gfp/+mice microglial activation and retinal degeneration[3]. STF-31 (10 mg/kg; i.p.) promotes accumulation of necrotic thymocytes after Dexamethasone-induced apoptosis in vivo[4].
Animal Model: | Twelve-week old C57BL/6J andCX3CR1gfp/+mice[3] | Dosage: | 10 mg/kg | Administration: | I.p. injections; twice daily for 2 days, followed by once daily for another 3 days | Result: | Improved photoreceptor survival and reduced microglial activation ofCX3CR1gfp/+mice, and not induced any C57BL/6J mice retinal cell death. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 34 mg/mL(80.28 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.3611 mL | 11.8055 mL | 23.6111 mL | 5 mM | 0.4722 mL | 2.3611 mL | 4.7222 mL | 10 mM | 0.2361 mL | 1.1806 mL | 2.3611 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2.5 mg/mL (5.90 mM); Clear solution; Need ultrasonic
此方案可获得 2.5 mg/mL (5.90 mM) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.90 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|